Invokana Lawsuit Alleges Link with Diabetic Ketoacidosis Seeking $10m In Damages

April 24, 2016 – – TheProductLawyers.com announces an additional lawsuit against the makers of Invokana, Janssen Pharmaceuticals, a branch of Johnson and Johnson Corporation. The Texas resident bringing the suit against Janssen alleges that the drug Invokana is responsible for severe injuries and the development of diabetic ketoacidosis (DKA), a condition in which potentially hazardous blood acids called ketones build up in the bloodstream. The lawsuit, filed in New Jersey late in 2015, seeks damages and compensation in the amount of $10 million, for past and future medical expenses linked with these injuries.

In 2013, the woman was prescribed Invokana as part of a diabetic maintenance regimen by her physician. The drug belongs to a group of drugs known as SGLT2 class inhibitors that assist in glucose maintenance. They are known to act by diverting a portion of glucose from the bloodstream directly to the kidneys, and then inhibiting the reuptake of sugars. The glucose is then directly eliminated from the body. However, such processes can place stress on the entire renal system.

The Texas woman claims that only one month after the drug was prescribed—November of 2013—she began to experience complications. Tests confirmed that she was experiencing DKA, and that she had suffered significant damage to her kidneys. While she ceased taking Invokana immediately, the injuries sustained are not of a temporary nature. As stated in her suit, the kidney damage is both severe and irreparable, which will entail future medical expenses.

Diabetic ketoacidosis has been associated with the use of SGLT2 class inhibitors such as Invokana. While the condition is usually developed due to lack of insulin with which the body can process blood glucose, it is not rare among diabetics. Associated conditions that can accompany DKA are severe infections or acute pancreatitis. The U.S. FDA has issued statements regarding concern for the adequate expression of DKA warnings on drug labels. While the FDA approved the drug for use in 2013, the agency has received adverse events reports that link Invokana and other drugs of its class to complications such as kidney damage, renal failure, and diabetic ketoacidosis.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009497